Renal Cell Carcinoma Market Growth Steady to 2023 Says a Global EpiCast Report

Jun 27, 2016, 02:00 ET from ReportsnReports

PUNE, India, June 27, 2016 /PRNewswire/ --

ReportsnReports.com adds "EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023" market research report providing an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (at 20-year intervals, starting at age 20 years and ending at ages =80 years) and sex. It also includes a forecast of the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, it provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.

Complete report on Renal Cell Carcinoma Epidemiology Forecast to 2023 of 43 pages with 14 tables and 6 figures is now available at http://www.reportsnreports.com/reports/296701-epicast-report-renal-cell-carcinoma-epidemiology-forecast-to-2023.html .

Epidemiologists forecast an increase in the diagnosed incident cases of RCC in the 8MM, from 190,147 diagnosed incident cases in 2013 to 309,734 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 6.29% during the forecast period. In 2023, urban China will have the highest number of diagnosed incident cases of RCC in the 8MM, with 147,457 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of RCC, with 7,591 diagnosed incident cases. Similarly, as shown in the second figure below, the five-year diagnosed prevalent cases of RCC in the 8MM will increase from 600,261 diagnosed prevalent cases in 2013 to 966,190 diagnosed prevalent cases in 2023, with an AGR of 6.10% during the forecast period.

The increase in the diagnosed five-year prevalent cases of RCC is partly attributed to the rising trend in the incidence rate of RCC in the 8MM, combined with changes in the population demographics in the respective markets. The rising trend in the incidence of RCC may partly be a result of increased use of imaging techniques that can detect asymptomatic tumors.

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of all cases in adults. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed yearly, and 116,000 people die from the disease.

Order a copy of Renal Cell Carcinoma - Epidemiology Forecast to 2023 market research report at http://www.reportsnreports.com/Purchase.aspx?name=296701 .

Another newly published market research titled EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025 provides an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of <1 year and 1-4 years, then in 10 year age groups to =65 years), and laboratory-confirmed incident cases of serogroup B, serogroup C, serogroup Y, and all other IMD combined. For Japan, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD segmented by sex and age (<1 year and =1 year); and a 10-year epidemiological forecast for laboratory-confirmed incident cases of specific serogroups. For the US, this report also provides a 10-year forecast of the number of first-year college students and the number of first-year college students living in campus accommodation. Complete report on Meningococcal Disease market research report of 82 pages is available at http://www.reportsnreports.com/reports/602727-epicast-report-meningococcal-disease-epidemiology-forecast-to-2025.html .

Explore more reports on Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:

Facebook:  https://www.facebook.com/ReportsnReports/

LinkedIn:  https://www.linkedin.com/company/reportsnreports

Twitter:  https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports